Blood test may replace tissue biopsies for ovarian cancer monitoring

NCT ID NCT04511988

Ongoing Knowledge-focused Sponsor: Institut de Cancérologie de Lorraine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether a simple blood test (liquid biopsy) can track how ovarian cancer changes over time, instead of taking multiple tissue samples. Twenty newly diagnosed patients will give blood and tissue samples during their treatment for up to two years. The goal is to see if the amount of DNA in the blood can predict if the cancer comes back, spreads, or leads to death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that a simple blood test can monitor ovarian cancer changes, potentially reducing the need for repeated tissue biopsies.
What could go wrong: This is a very small pilot study with only 20 patients, so results may not apply to everyone. It is designed to test feasibility, not to prove a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE ENDOMETRIOID CARCINOMA OF OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL ORIGIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, 54506, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.